Skip to main content
GutCited

Omega-3 Fatty Acids (EPA/DHA) für Ulcerative Colitis (UC)

C

Mixed results in maintaining UC remission. Some meta-analyses show modest benefit; others show no significant effect. EPA may be more beneficial than DHA.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Domega\u002D3\u002Dfatty\u002Dacids\u0026condition\u003Dibd\u002Dulcerative\u002Dcolitis'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

C

Fazit

Mixed results in maintaining UC remission. Some meta-analyses show modest benefit; others show no significant effect. EPA may be more beneficial than DHA.

Key Study Findings

Review
Diet in Ulcerative Colitis: A Narrative Review of Its Role in Pathogenesis and Treatment.
Dose: None vs.: None Outcome: None Wirkung: None None

Population: patients with ulcerative colitis

Review
Are there Effective Vegan-Friendly Supplements for Optimizing Health and Sports Performance? a Narrative Review.
Dose: None vs.: None Outcome: Athletic performance and nutritional optimization Wirkung: None None

Population: Vegan athletes (narrative review)

Review
From Evidence to Practice: A Narrative Framework for Integrating the Mediterranean Diet into Inflammatory Bowel …
Dose: None vs.: None Outcome: None Wirkung: None None

Population: None

Review
Gut microbiome-centric nutritional strategies in inflammatory bowel disease: Modulating dysbiosis for therapeutic benefit.
Dose: None vs.: None Outcome: IBD microbiota modulation and immune regulation Wirkung: None None

Population: IBD patients (review of nutritional interventions)

Review
Association between Omega-3 fatty acids and autoimmune disease: Evidence from the umbrella review and Mendelian …
Dose: None vs.: None Outcome: Colitis severity Wirkung: None None

Population: Crohn's disease patients

Other
Interaction between diet and genetics in patients with inflammatory bowel disease.
Dose: None vs.: None Outcome: Diet-genetics interaction in IBD Wirkung: None None

Population: IBD patients (editorial commentary)

Key Statistics

8

Studien

1000

Teilnehmer

Mixed

C

Bewertung

Referenced Papers

Nutrients 2022 61 Zitierungen
Gastroenterology clinics of … 2018 67 Zitierungen
Medical principles and … 2017 45 Zitierungen
Annals of gastroenterology 2016 80 Zitierungen
European journal of … 2016 79 Zitierungen
Clinics in dermatology 2016 19 Zitierungen
World journal of … 2014 25 Zitierungen
Alimentary pharmacology & … 2013 128 Zitierungen
The British journal … 2012 145 Zitierungen
The Cochrane database … 2012 130 Zitierungen
JRSM short reports 2010 11 Zitierungen
The Cochrane database … 2007 118 Zitierungen
Journal of the … 2002 2016 Zitierungen
Nutrition (Burbank, Los … 2000 64 Zitierungen
Drugs 1998 99 Zitierungen
The American journal … 1998 84 Zitierungen
Bailliere's clinical gastroenterology 1997 26 Zitierungen
The American journal … 1991 2278 Zitierungen

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Übliche Dosierungen

general:
1,000-2,000 mg combined EPA/DHA per day
ibdsupport:
2,000-4,000 mg/day combined EPA/DHA (higher EPA ratio may be more beneficial)

Obergrenze: 3,000 mg/day combined EPA/DHA (FDA GRAS limit)

In der Forschung untersuchte Dosierungen

Dosierung Dauer Wirkung N
None -- Mixed --
None -- Positive --
None -- Mixed --
None -- Positive --
None -- Neutral --
None -- Neutral --
95% -- Mixed 124
95% -- Mixed --

Beste Einnahmezeit: With meals containing fat for better absorption

Safety & Side Effects

Gemeldete Nebenwirkungen

  • Fishy aftertaste and burping
  • Mild gastrointestinal discomfort (nausea, diarrhea)
  • Potential increased bleeding time at very high doses (>3 g/day)
  • May lower blood pressure slightly

Bekannte Wechselwirkungen

  • Anticoagulants and antiplatelet drugs (may increase bleeding risk at high doses)
  • Blood pressure medications (additive hypotensive effect)
  • Orlistat (may reduce omega-3 absorption)
  • Cyclosporine (fish oil may reduce cyclosporine nephrotoxicity but monitor levels)

Tolerierbare Höchstaufnahmemenge: 3,000 mg/day combined EPA/DHA (FDA GRAS limit)

Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.

Frequently Asked Questions

Does Omega-3 Fatty Acids (EPA/DHA) help with Ulcerative Colitis (UC)?
Based on 8 studies with 1,000 participants, there is limited but promising evidence that Omega-3 Fatty Acids (EPA/DHA) may support Ulcerative Colitis (UC) management. Our evidence grade is C (Some Evidence).
How much Omega-3 Fatty Acids (EPA/DHA) should I take for Ulcerative Colitis (UC)?
Studies have used various dosages. A commonly studied range is 1,000-2,000 mg combined EPA/DHA per day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Omega-3 Fatty Acids (EPA/DHA)?
Reported side effects may include Fishy aftertaste and burping, Mild gastrointestinal discomfort (nausea, diarrhea), Potential increased bleeding time at very high doses (>3 g/day), May lower blood pressure slightly. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Omega-3 Fatty Acids (EPA/DHA) and Ulcerative Colitis (UC)?
We rate the evidence as Grade C (Some Evidence). This rating is based on 8 peer-reviewed studies with 1,000 total participants. The overall direction of effect is mixed.

Related Evidence

Omega-3 Fatty Acids (EPA/DHA) für andere Beschwerden

FDA-Haftungsausschluss: Diese Aussagen wurden nicht von der Food and Drug Administration bewertet. Die Produkte und Informationen auf dieser Website sind nicht dazu bestimmt, Krankheiten zu diagnostizieren, zu behandeln, zu heilen oder zu verhindern. Die dargestellten Evidenzbewertungen basieren auf unserer Analyse veröffentlichter begutachteter Forschung und stellen keine medizinische Beratung dar. Konsultieren Sie immer Ihren Arzt, bevor Sie mit der Einnahme von Nahrungsergänzungsmitteln beginnen.